Literature DB >> 15324924

Physicochemical studies on the stability of influenza haemagglutinin in vaccine bulk material.

Dion M A M Luykx1, Marco G Casteleijn, Wim Jiskoot, Janny Westdijk, Peter M J M Jongen.   

Abstract

The relative unknown conformational stability of monovalent bulks of influenza virus haemagglutinin (HA) from three different strains (B/Guangdong, A/New Caledonia and A/Panama) was investigated with fluorescence and circular dichroism (CD) spectroscopy. Various stress conditions (concentration of denaturant, freeze-thawing, pH and temperature) affected the spectroscopic properties of the haemagglutinin proteins differently. Unfolding experiments revealed a poor stability of Guangdong haemagglutinin (GD-HA) in comparison with New Caledonia (NC-HA) and Panama haemagglutinin (P-HA). Freeze-thawing altered the secondary and tertiary structure of Guangdong haemagglutinin and only the tertiary structure of Panama haemagglutinin. From pH 4.6-9.2 the tertiary structures of Guangdong, New Caledonia and Panama haemagglutinin were all affected to a different extent. The secondary structure was only altered at low pH. Incubation of haemagglutinin at 60 degrees C resulted in denaturation of the protein and a dramatic change of the fluorescence spectrum, indicative of oxidised tryptophan (Trp). In conclusion, fluorescence and circular dichroism spectroscopy are highly suitable techniques to monitor the stability of haemagglutinin in a straightforward and fast way.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15324924     DOI: 10.1016/j.ejps.2004.05.007

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  10 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

2.  Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine.

Authors:  Senthil Murugappan; Harshad P Patil; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs
Journal:  AAPS J       Date:  2014-01-31       Impact factor: 4.009

Review 3.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

4.  The osmotic stress response of split influenza vaccine particles in an acidic environment.

Authors:  Hyo-Jick Choi; Min-Chul Kim; Sang-Moo Kang; Carlo D Montemagno
Journal:  Arch Pharm Res       Date:  2013-10-08       Impact factor: 4.946

5.  Evaluation of Epic® label-free technology to quantify functional recombinant hemagglutinin.

Authors:  Lianlian Jiang; Maryna C Eichelberger
Journal:  Biol Proced Online       Date:  2015-03-09       Impact factor: 3.244

6.  Development of a Freeze-Dried, Heat-Stable Influenza Subunit Vaccine Formulation.

Authors:  Alexander Flood; Marcus Estrada; David McAdams; Yuhua Ji; Dexiang Chen
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

7.  Confronting the next pandemic--workshop on lessons learned from potency testing of pandemic (H1N1) 2009 influenza vaccines and considerations for future potency tests, Ottawa, Canada, July 27-29, 2010.

Authors:  Stephanie Hardy; Maryna Eichelberger; Elwyn Griffiths; Jerry P Weir; David Wood; Claudia Alfonso
Journal:  Influenza Other Respir Viruses       Date:  2011-04-07       Impact factor: 4.380

8.  Analysis of Biologics Molecular Descriptors towards Predictive Modelling for Protein Drug Development Using Time-Gated Raman Spectroscopy.

Authors:  Jaakko Itkonen; Leo Ghemtio; Daniela Pellegrino; Pia J Jokela Née Heinonen; Henri Xhaard; Marco G Casteleijn
Journal:  Pharmaceutics       Date:  2022-08-05       Impact factor: 6.525

9.  A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Authors:  Anwar M Hashem; Caroline Gravel; Aaron Farnsworth; Wei Zou; Michelle Lemieux; Kangwei Xu; Changgui Li; Junzhi Wang; Marie-France Goneau; Maria Merziotis; Runtao He; Michel Gilbert; Xuguang Li
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

10.  Transcutaneous delivery and thermostability of a dry trivalent inactivated influenza vaccine patch.

Authors:  Vladimir G Frolov; Robert C Seid; Olabisi Odutayo; Mohammad Al-Khalili; Jianmei Yu; Olga Y Frolova; Hong Vu; Barbara A Butler; Jee Loon Look; Larry R Ellingsworth; Gregory M Glenn
Journal:  Influenza Other Respir Viruses       Date:  2008-03       Impact factor: 4.380

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.